Inclusion Criteria:

- In Part A: histological or cytological diagnosis of solid tumor, progressive
metastatic disease, or progressive locally advanced disease not amenable to local
therapy

- In Part B: histologically- or cytologically-confirmed diagnosis of NSCLC (Stage
IIIB/IV)

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

- Adequate organ function

Exclusion criteria:

- Cancer therapy within 4 weeks prior to the first dose of study therapy, or not
recovered from the adverse events of agents administered more than 4 weeks prior to
the first dose of study therapy.

- Currently participating or has participated in a study with an investigational agent
or using an investigational device within 30 days of first dose of study therapy

- Expected to require any other form of antineoplastic therapy while on study

- On chronic systemic steroid therapy within two weeks prior to the first dose of trial
treatment or on any other form of immunosuppressive medication